ExpressEye is used to measure the saccadic movements of the eye and classify a subject's performance in different tasks as normal or abnormal. Subjects are patients above the age of 6 years with suspicion of problems in dynamic vision and/or optomotor control.
ExpressEye can be used in any case of problems in the optomotor domain. The measured horizontal eye movements of a person made in response to generated stimuli are analysed to nontonial cyc inovential or a person's fixation and reflexive and voluntary eye movement control.

Device Description

ExpressEye measures horizontal eye movements and analyses the fixation quality, direction and reaction time of fast eye movements. The device consists of a head band, which carries light sources for visual stimuli, an amplifier, and infrared light emmitting/receiving elements. A hand held processor controls the stimuli and analyses the eye movement signals. Optional the user can transfer the data to a personal computer.

AI/ML Overview

The device, ExpressEye, is an eye movement recorder that measures horizontal eye movements and analyzes fixation quality, direction, and reaction time of fast eye movements.

Here's an analysis based on the provided text:

Acceptance Criteria and Device Performance

Acceptance Criteria	Reported Device Performance
Laser power output (Class II classification)	0.2 milliwatts (5 times less than permitted for a Class 2 device)
Infrared light spectral radiance	Inside the Threshold Limit Value recommended by the American Conference of Governmental Industrial Hygienists
Electromagnetic compatibility	Below the level allowed for Class A (certified by FCC-approved laboratory)
Biocompatibility of materials	Materials of the head band are declared biocompatible and conformant to European and US regulations
Safety of additional data analysis	"The additional acquirement of variables from the eye movement traces does not affect the safety because it results in recommendations of training procedures, not in any kind of medication."

Study Information

Sample size used for the test set and the data provenance: Not mentioned.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not mentioned.
Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not mentioned.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not mentioned. The device's primary function is described as measurement and analysis of eye movements, not as an AI-assisted diagnostic tool for human readers.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: The provided text primarily focuses on the device's technical specifications and safety compliance for regulatory approval (510(k)). It describes the device as measuring and analyzing eye movements, but it does not detail a specific performance study in terms of diagnostic accuracy or comparison to a gold standard. The "Summary and conclusion of technical tests" section indicates physical and electrical safety tests, but not a clinical or standalone performance study in the context of diagnostic accuracy.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not mentioned.
The sample size for the training set: Not mentioned.
How the ground truth for the training set was established: Not mentioned.

Overall Conclusion from the Provided Text:

The provided document is a 510(k) summary for regulatory clearance, primarily focusing on demonstrating substantial equivalence to a predicate device and adherence to safety standards (laser safety, infrared light, EMC, biocompatibility). It describes the device's intended use and technical features. However, it does not contain information about a clinical performance study that would typically include details such as sample sizes, ground truth establishment, expert readers, or comparative effectiveness studies regarding its analytical capabilities (e.g., classifying a subject's performance as normal or abnormal). The "Summary and conclusion of technical tests" section addresses safety and compliance, not clinical performance metrics for diagnosis.

Summary

{0}------------------------------------------------

6979423

AUG 12 1999

7-15-1999

510(k) Summary

Submitted by: Optomotor Laboratories BBL Fischer Tivolistr. 11 D - 79104 Freiburg Germany +49 761 2922600 Phone: Phone: +49 761 2922699 Fax:

Contact:

Prof. Dr. rer. nat. Burkhart Fischer

Trade Name:

ExpressEye

Common Name:

Eve Movement Recorder

Classification:

Class II, 21 CFR 882.1460, Nystagmograph

Device Description:

Intended Use:

Substantial Equivalence:

House Infrared/Video ExpressEye is substantially equivalent to the The Electronystagmograph System by Eye Dynamics, Inc. Both devices measure the movements of the eye by infrared light corneal reflection. Both instruments allow to display fast and slow eye movements. While ExpressEye analyses fast eye movements (saccades) the Nystagmograph permits viewing of the eyes and recording on video tape. Most technical details such as infrared illumination are the same. ExpressEye additionally generates visual target stimuli and provides appropriate analysis.

{1}------------------------------------------------

5992423
5

Summary of comparison with the predicate Device:

Item	ExpressEye	House IR/Video
Intended use	(Identical, with additional data analysis in ExpressEye)
Sensor	video camera	phototransistors
Light source	infrared LEDsPeak Wavelength= 940 nm	infrared LEDsPeak Wavelength= 950 nm
Headmounting	plastic head band	eye goggles
Target projector	mini Lasers withlow energy (Class II)	not present

Summary and conclusion of technical tests:

Laser:

The device meets the performance standard 21 CFR Part 1040 (light emitting products) part 10 (laser products). The lasers are classified as Laser Class 2. The use of the lasers to project visual targets on a surface in front of the test person is save, because the power of the lasers is only 0.2 milliwatts, 5 times less than permitted for a laser class 2 device.

Infrared light:

the infrared light used by the device has a spectral radiance inside the Threshold Limit Value recommended by the American Conference of Governmental Industrial Hygienists.

Electromagnetic Interference:

The electromagnetic compatibility was measured by a laboratory approved by the U.S. FCC. They certified that the radiation is below the level allowed for class A. Therefore the following text appears in the device manual:

Warning - This is a Class A product. In a domestic environment this product may cause radio interference in which case the user may be required to take adequate measures.

The disturbance of the device by outside radiation found in the measurement is eliminated by added shielding.

Biocompatibility:

The materials of the head band are declared biocompatible and comformant to European and US regulations by the manufacturer of the head band.

The additional acquirement of variables from the eye movement traces does not affect the safety because it results in recommendations of training procedures, not in any kind of medication.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing right, with flowing lines beneath them, resembling water or fabric.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 1:2 1999

Dr. Burkhart Fischer Optomotor Laboratories Tivolistr. 1 1 D-79104 Freiburg Germany

Re: K992473 Trade Name: ExpressEye Regulatory Class: II Product Code: GWN Dated: July 15, 1999 Received: July 26, 1999

Dear Dr. Fischer:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

Page 2 – Dr. Burkhart Fischer

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,
bastula

Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

1 Indications for Use

ExpressEye can be used in any case of problems in the optomotor domain. The measured horizontal eye movements of a person made in response to generated stimuli are analysed to nontonial cyc inovential or a person's fixation and reflexive and voluntary eye movement control.

(Division Si Division of Ger 1992473 510(k) Number

Prescription Use
(Per 21 CFR 801.109)

Regulation Number and Section

§ 882.1460 Nystagmograph.

(a)
Identification. A nystagmograph is a device used to measure, record, or visually display the involuntary movements (nystagmus) of the eyeball.(b)
Classification. Class II (performance standards).